PON2 and PPARG polymorphisms as biomarkers of risk for coronary heart disease

Biomark Med. 2018 Mar;12(3):287-297. doi: 10.2217/bmm-2017-0227. Epub 2018 Feb 14.

Abstract

Aim: Investigate the correlation between paraoxonase 2 (PON2) Ser311Cys polymorphism as well as the peroxisome proliferator-activated receptor gamma (PPARG) His477His polymorphism and the susceptibility to development of coronary heart diseases (CHD) through a meta-analysis.

Methods: Odds ratio and the corresponding 95% CI were used to assess the results. We included 7476 CHD patients and 8504 healthy controls. All the statistical analyses were performed by Comprehensive Meta-Analysis software (CMA, version 2.0).

Results: The Ser311Cys polymorphism decreased susceptibility in the overall population and Asian population to CHD. The His477His polymorphism has a protective role in the overall population; however, the subgroup analysis by ethnicity suggested that in Asian population, His477His might increase the risk of CHD.

Conclusion: These polymorphisms constitute important predictive indicators of CHD susceptibility.

Keywords: genes; heart diseases; meta-analysis; polymorphisms; systematic review.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Aryldialkylphosphatase / genetics*
  • Biomarkers / metabolism*
  • Coronary Disease / diagnosis*
  • Coronary Disease / genetics
  • Genetic Predisposition to Disease
  • Humans
  • Meta-Analysis as Topic
  • Odds Ratio
  • PPAR gamma / genetics*
  • Polymorphism, Single Nucleotide
  • Risk Factors

Substances

  • Biomarkers
  • PPAR gamma
  • Aryldialkylphosphatase
  • PON2 protein, human